While Agios Pharmaceuticals Inc has underperformed by -11.99%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO rose by 73.50%, with highs and lows ranging from $62.58 to $20.96, whereas the simple moving average fell by -9.01% in the last 200 days.
On October 16, 2024, Scotiabank started tracking Agios Pharmaceuticals Inc (NASDAQ: AGIO) recommending Sector Outperform. Leerink Partners also Downgraded AGIO shares as ‘Market Perform’, setting a target price of $56 on the company’s shares in a report dated September 27, 2024. Piper Sandler initiated its ‘Overweight’ rating for AGIO, as published in its report on February 03, 2023. Goldman’s report from November 17, 2022 suggests a price prediction of $32 for AGIO shares, giving the stock a ‘Neutral’ rating. SVB Leerink also rated the stock as ‘Outperform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Agios Pharmaceuticals Inc (AGIO)
Further, the quarter-over-quarter increase in sales is 21.15%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Agios Pharmaceuticals Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 53.65% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.77, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and AGIO is recording an average volume of 680.64K. On a monthly basis, the volatility of the stock is set at 6.58%, whereas on a weekly basis, it is put at 14.41%, with a loss of -35.27% over the past seven days. Furthermore, long-term investors anticipate a median target price of $56.88, showing growth from the present price of $38.17, which can serve as yet another indication of whether AGIO is worth investing in or should be passed over.
How Do You Analyze Agios Pharmaceuticals Inc Shares?
A leading company in the Biotechnology sector, Agios Pharmaceuticals Inc (AGIO) is based in the USA. When comparing Agios Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 3.36, there is a growth in quarterly earnings of 1091.28%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.32%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 104.72% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AGIO shares are owned by institutional investors to the tune of 104.72% at present.
